BioMarin Pharmaceutical, Inc. (BMRN)

61.29 +1.22 (+2.03%) USD  |  NASDAQ  |  Jan 07, 16:00
61.29 0.00 (0.00%) After-Hours: 18:01
More

BioMarin Pharmaceutical Research and Development Expense (Annual): 747.18M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for BMRN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Amicus Therapeutics, Inc. 109.36M
Gilead Sciences, Inc. 5.816B
Merck & Co., Inc. 15.79B
AbbVie, Inc. 8.315B
Bristol Myers Squibb Co. 9.782B